Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.
解鎖市場時間軸與訊號動態
過去 90 日內有 1,059 個訊號。
此公司進入各市場的次序 — 由最舊至最新
Quality Engineering, QA Expert, Commissioning & Qualification Audit and Inspection Support
註冊以查看完整訊號動態
Lonza 的國際擴張與競爭對手的比較
Lonza你長條顯示所比較各公司之間的相對規模。
5 項指標| 公司 | 市場 | 新市場 | 動能 | 活動 | 擴張評分 |
|---|---|---|---|---|---|
 Lonza你 | 25 | 0 | -18% | 988 | 33 |
急速擴張 — 過去 90 日內開放了 911 個職位，較上一期上升 172%。 以 Engineering 為主，集中於 瑞士。
Hyderabad, Telangana, India · 今日
Quality Engineering, QA Expert, Commissioning & Qualification Audit and Inspection Support
Slough, England, United Kingdom · 前日
Associate Principal QA Specialist
Gurugram, Haryana, India · 昨日
IT Commercial Head
整個技術架構共偵測到 36 項技術。
於 188 個市場進行 14 個活躍廣告活動。
已結束過去 90 日內有 18 則提及。
和鉑醫藥公佈2026年上半年收入8.34億人民幣(按年增長20.9%),淨利潤4.42億人民幣,連續七個半年度盈利,多項臨床里程碑及戰略合作取得進展。
基於AI的抗體藥物開發平台Mirabo Biotechnology在Stonebridge Ventures領投、FuturePlay參與下,完成40億韓元(約300萬美元)Pre-A輪融資,使用其MiRAiQ AI引擎。
Artisan Partners在第四季度建倉GE Aerospace、康寧、意法半導體和Robinhood,同時增持DoorDash和基恩士。該公司退出Cencora、龍沙集團和Medline,並減持AMD、Lam、Amer Sports和騰訊。
解鎖已驗證電郵與直撥電話
免費 · 無需信用卡
關於 Lonza 業務、市場及增長訊號的快速解答。
